Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FPE015 is a trispecific antibody developed by Guangdong Fapon Biopharma. It targets three immune checkpoint proteins—CD112R (also known as PVRIG), PD-L1 (Programmed death-ligand 1), and TIGIT (T cell immunoglobulin and ITIM domains). The drug acts as an antagonist or inhibitor to these targets, aiming to enhance anti-tumor immune responses by blocking multiple inhibitory pathways that suppress T-cell activity in the tumor microenvironment. Its primary therapeutic area was neoplasms (cancer). Development of FPE015 has been discontinued at the preclinical stage[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FPE015.